Influenza virus vaccination of patients with chronic lung disease

Chest

Volumn 112, Issue 5, 1997, Pages 1221-1233

  Gorse, Geoffrey J ^a,b,d   Otto, Esther E ^b   Daughaday, Carlos C ^a   Newman, Frances K ^b   Eickhoff, Christopher S ^b   Powers, Douglas C ^a,b,c   Lusk, Rodney H ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Cellular immunity; Chronic lung disease; Immune response; Influenza A virus; Mucosal immunity; Virus vaccines

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; LIVE VACCINE; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SPIROMETRY;

EID: 0030697357     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.5.1221     Document Type: Article

References (71)

1. Advisory Committee on Immunization Practices. Prevention and control of influenza. MMWR 1993; 42(No. RR-6):1-14
2. Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961; 176:776-82
3. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987; 82(suppl 6A):20-25
4. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980; 112:798-811
5. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis 1987; 136:550-55
6. Foster DA, Talsma AN, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136:296-307
7. Nichol KL, Margolis KL, Wuorenma J. et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778-84
8. Gross PA, Quinnan GV Jr, Weksler ME, et al. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine 1989; 7:303-08
9. Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4:38-44
10. Treanor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117:625-33
11. Gorse GJ, Gampbell MJ, Otto EE, et al. Increased anti influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 1995; 172:1-10
12. Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol 1990; 28:2539-50
13. Gorse GJ, Belshe RB, Munn NJ. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 1991; 100:977-84
14. Gorse GJ, Otto EE, Powers DC, et al. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J Infect Dis 1996; 173:285-90
15. Belshe RB, Van Voris LP, Bartram J, et al. Live attenuated influenza A virus vaccines in children: results of a field trial. J Infect Dis 1984; 150:834-40
16. Johnson PR, Feldman S, Thompson JM, et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986; 154:121-27
17. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984; 1:705-08
18. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23:66-72
19. Gorse GJ, Belshe RB, Munn NJ. Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. J Clin Microbiol 1986; 24:336-42
20. Gorse GJ, Belshe RB, Munn NJ. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol 1988; 26:911-18
21. Powers DC, Sears SD, Murphy BR, et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989; 27:2666-71
22. Powers DC, Fries LF, Murphy BR, et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991; 29:498-505
23. Zahradnik JM, Kasel JA, Martin RR, et al. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine. J Med Virol 1983; 11:277-85
24. Gorse GJ, Belshe RB. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand J Infect Dis 1991; 23:7-17
25. Ennis FA, Yi-Hua Q, Schild GC. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J Gen Virol 1982; 58:273-81
26. Hay, AJ, Belshe RB. Anderson EL, et al. Influenza viruses. In: Belshe RB, ed. Textbook of human virology. 2nd ed. St.Louis: Mosby-Year Book, 1991; 307-41
27. Clements ML, Betts RF, Tierney EL., et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986: 24:157-60
28. McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T cell immunity to influenza. N Engl J Med 1983; 309:13-17
29. Clements ML, Betts RF, Tierney EL. et al. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986; 23:73-76
30. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68-76
31. Mossman TR, Coffman RL, TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7:145-73
32. Goldsmith MA, Greene WC. Interleukin 2 and the niterleukin-2 receptor. In: Thomson AW, ed. The cytokine handbook. London: Academic Press, 1994; 57-80
33. McElhaney JE, Meneilly GS, Beattie BL, et al. The effect of influenza vaccination on IL2 production in healthy elderly: implications for current vaccination practices. J Gerontol 1992; 47:M3-8
34. McElhaney JE, Meneilly GS, Lechelt KE, et al. Split-virus influenza vaccines: do they provide adequate immunity in the elderly? J Gerontol 1994; 49:M37-43
35. McElhaney JE, Meneilly GS, Pinkoski MJ, et al. Vaccine-related determinants of the interleukin-2 response to influenza vaccination in healthy young and elderly adults. Vaccine 1995: 13:6-10
36. Locksley RM. Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci USA 1993; 90:5879-80
37. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993; 260:496-97
38. De Maeyer E, De Maeyer-Guignard J. Interferons. In: Thomson AW. ed. The cytokine handbook. London: Academic Press, 1994; 265-88
39. Baumgarth N. Brown L, Jackson D, et al. Novel features of the respiratory tract T-cell response to influenza virus infection: lung T cells increase expression of gamma interferon mRNA in vivo and maintain high levels of mRNA expression for interleukin-5 (IL-5) and IL-10. J Virol 1994; 68:7575-81
40. Boom WH, Liano D, Abbas AK. Heterogeneity of helper/ inducer T lymphocytes: H. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes. J Exp Med 1988; 167:1350-63
41. Murray PD, McKenzie DT, Swain SL, et al. Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression. J Immunol 1987; 139:2669-75
42. Bancherean J, Rybak ME. Interleukin 4. In: Thomson AW, ed. The cytokine handbook. London: Academic Press, 1994; 99-126
43. Horohov DW, Crim JA, Smith PL, et al. IL-4 (B cell-stimulatory factor 1 regulates multiple aspects of influenza-specific cell-mediated immunity. J Immunol 1988; 141:4217-23
44. Widmer MB, Grabstein KH. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature 1987; 326:795-98
45. Widmer MB, Acres RB. Sassenfeld HM, et al. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor I (interleukin 4). J Exp Med 1987; 166: 1447-55
46. Maassab HF. Biologie and immunologie characteristics of cold-adapted influenza virus. J Immunol 1969; 102:728-32
47. Cox NJ, Maassab HF, Kendal AP. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: non-random reassortment of genes during preparation of live virus vaccine candidates by recombination at 25° between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/60. Virology 1979; 97:190-94
48. American College of Chest Physicians. Report of the Section on Respiratory Pathophysiology: statement on spirometry. Chest 1983; 83:547-50
49. Gardner RM. Standardization of spirometry: a summary of recommendations from the American Thoracic Society; the 1987 update. Ann Intern Med 1988; 108:217-20
50. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-34
51. Medical Section of the American Lung Association. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-18
52. Belshe RB, Van Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 1982; 145:311-19
53. Reed LJ, Muench H. Simple method of estimating 50 percent endpoints. Am J Hyg 1938: 27:493-97
54. Dowdle WR, Kendal AP, Noble GR. Influenza viruses. In: Leunnette EH, Schmidt NJ, eds. Diagnostic procedures for viral, rickettsial. and chlamydial infections. 5th ed. Washington, DC: American Public Health Association, 1979; 585-609
55. Murphy BR, Phelan MA, Nelson DL, et al. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981; 13:554-60
56. Murphy BR, Nelson DL, Wright PF, et al. Secretary and systemic immunological response in children infected with live-attenuated influenza A virus vaccines. Infect Immun 1982; 36:1102-08
57. Boyum A. Isolation of mononuclear cells and gramilocytes from human blood. Scand J Clin Lab Invest 1968; 21(suppl): 77-89
58. Centers for Disease Control and Prevention. Influenza surveillance - United States, 1991-92. In: CDC Surveillance summaries. September 4, 1992. MMWR 1992; 41(No. SS-5): 35-43
59. Centers for Disease Control. Update: influenza activity - United States and worldwide, and composition of the 1993-94 influenza vaccine. MMWR 1993; 42:177-80
60. Centers for Disease Control. Update: influenza activity - United States and worldwide, 1993-94 season, and composition of the 1994-95 influenza vaccine, MMWR 1994; 43: 179-83
61. MRC Advisory Group on Pulmonary Function Tests in Relation to Live Influenza Vaccines. Trials of live attenuated influenza virus vaccine in patients with chronic obstructive airways diseases. Br J Dis Chest 1984; 78:236-47
62. Keitel WA, Cate TR, Atmar RL, et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol 1996; 3:507-10
63. Tomoda T, Morita H, Kurashige T, et al. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-γ production and local IgA response. Vaccine 1995; 13:185-90
64. Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med 1986; 164:1114-28
65. Swain SL, Dennert G, Warner JF, et al. Culture superuatants of a stimulated T-Cell line have helper activity that acts synergistically with interleukin 2 in the response of B cells to antigen. Proc Natl Acad Sci USA 1981; 78:2517-21
66. Palladino G, Scherle PA, Gerhard W. Activity of CD4+ T-Cell clones of type 1 and type 2 in generation of influenza virus-specific cytotoxic responses in vitro. J Virol 1991; 65:6071-76
67. Braakman E, Treep-Van Leeuwen P, Roosnek EE, et al. The role of IL-2 and T4+ cells in the generation of human influenza virus-specific CTL activitv. Cell Immunol 1986; 100:462-73
68. Sarawar SR, Doherty PC. Concurrent production of interleukin-2, interleukin-10, and gamma interferon in the regional lymph nodes of mice with influenza pneumonia. J Virol 1994; 68:3112-19
69. Carding SR, Allan W, McMickle A, et al. Activation of cytokine genes in T cells during primary and secondary murine influenza pneumonia. J Exp Med 1993; 177:475-82
70. Craham MB, Braciale VL, Braciale TJ. Influenza virus-specific CD4+ T helper tyjie 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 1994: 180:1273-82
71. Moran TM, Isobe H, Fernandez-Sesma A, et al. Interleukin-4 causes delayed viral clearance in influenza virus-infected mice. J Virol 1996; 70:5230-34